Effect of varying degrees of renal impairment on the pharmacokinetics and tolerability of taspoglutide
Author:
Affiliation:
1. F. Hoffmann-La Roche AG; Basel Switzerland
2. Novartis Pharma AG; Basel Switzerland
3. Genentech; South San Francisco California
Funder
Roche
Publisher
Wiley
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12850/fullpdf
Reference44 articles.
1. Discovery and characterization of taspoglutide, a novel analogue of human glucagon-like peptide-1, engineered for sustained therapeutic activity in type 2 diabetes;Dong;Diabetes Obes Metab,2011
2. Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in vivo potency;Sebokova;Endocrinology,2010
3. BIM-51077, a dipeptidyl peptidase-IV-resistant glucagon-like peptide-1 analog;Giannoukakis;Curr Opin Investig Drugs,2007
4. Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with type 2 diabetes;Kapitza;Diabet Med,2009
5. Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study;Nauck;Diabetes Care,2009
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. New insights into nanomedicines for oral delivery of glucagon‐like peptide‐1 analogs;WIREs Nanomedicine and Nanobiotechnology;2024-03
2. Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study;Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy;2022-01
3. Assessment of Drug–Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials;Clinical Pharmacokinetics;2019-04-09
4. Semaglutide as a promising antiobesity drug;Obesity Reviews;2019-02-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3